File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.jtho.2018.09.021
- Scopus: eid_2-s2.0-85056510211
- PMID: 30292852
- WOS: WOS:000456410800028
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non–Small Cell Lung Cancer
Title | Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non–Small Cell Lung Cancer |
---|---|
Authors | |
Keywords | Non-small cell lung cancer Combined modality therapy Toxicity Adverse events Doses |
Issue Date | 2019 |
Publisher | Elsevier Inc. The Journal's web site is located at http://www.jto.org |
Citation | Journal of Thoracic Oncology, 2019, v. 14 n. 2, p. 298-303 How to Cite? |
Abstract | Objective:
Concurrent chemoradiotherapy (CRT) was the standard treatment for locally advanced NSCLC (LA-NSCLC). This study was performed to examine thoracic radiotherapy (TRT) parameters and their impact on adverse events (AEs).
Methods:
We collected individual patient data from 3600 patients with LA-NSCLC who participated in 16 cooperative group trials of concurrent CRT. The TRT parameters examined included field design strategy (elective nodal irradiation [ENI] versus involved-field [IF] TRT [IF-TRT]) and TRT dose (60 Gy versus ≥60 Gy). The primary end point of this analysis was the occurrence of AEs. ORs for AEs were calculated with univariable and multivariable logistic models.
Results:
TRT doses ranged from 60 to 74 Gy. ENI was not associated with more grade 3 or higher AEs than IF-TRT was (multivariable OR = 0.77, 95% confidence interval [CI]: 0.543–1.102, p = 0.1545). Doses higher than 60 Gy (high-dose TRT) were associated with significantly more grade 3 or higher AEs (multivariable OR = 1.82, 95% CI: 1.501–2.203, p < 0.0001). In contrast, ENI was associated with significantly more grade 4 or higher AEs (multivariable OR = 1.33, 95% CI: 1.035–1.709, p = 0.0258). Doses higher than 60 Gy were also associated with more grade 4 or higher AEs (multivariate OR = 1.42, 95% CI: 1.191–1.700, p = 0.0001). Grade 5 AEs plus treatment-related deaths were more frequent with higher-dose TRT (p = 0.0012) but not ENI (p = 0.099).
Conclusions:
For patients with LA-NSCLC treated with concurrent CRT, IF-TRT was not associated with the overall risk of grade 3 or higher AEs but was associated with significantly fewer grade 4 or higher AEs than ENI TRT. This is likely the result of irradiation of a lesser amount of adjacent critical normal tissue. Higher TRT doses were associated significantly with grade 3 or higher and grade 4 or higher AEs. On the basis of these findings and our prior report on survival, CRT using IF-TRT and 60 Gy (conventionally fractionated) were associated with more favorable patient survival and less toxicity than was the use of ENI or higher radiotherapy doses. |
Description | Link to Open archive |
Persistent Identifier | http://hdl.handle.net/10722/281827 |
ISSN | 2023 Impact Factor: 21.0 2023 SCImago Journal Rankings: 7.879 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Schild, SE | - |
dc.contributor.author | Fan, W | - |
dc.contributor.author | Stinchcombe, TE | - |
dc.contributor.author | Vokes, EE | - |
dc.contributor.author | Ramalingam, SS | - |
dc.contributor.author | Bradley, JD | - |
dc.contributor.author | Kelly, K | - |
dc.contributor.author | Pang, HH | - |
dc.contributor.author | Wang, X | - |
dc.date.accessioned | 2020-03-27T04:22:58Z | - |
dc.date.available | 2020-03-27T04:22:58Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Journal of Thoracic Oncology, 2019, v. 14 n. 2, p. 298-303 | - |
dc.identifier.issn | 1556-0864 | - |
dc.identifier.uri | http://hdl.handle.net/10722/281827 | - |
dc.description | Link to Open archive | - |
dc.description.abstract | Objective: Concurrent chemoradiotherapy (CRT) was the standard treatment for locally advanced NSCLC (LA-NSCLC). This study was performed to examine thoracic radiotherapy (TRT) parameters and their impact on adverse events (AEs). Methods: We collected individual patient data from 3600 patients with LA-NSCLC who participated in 16 cooperative group trials of concurrent CRT. The TRT parameters examined included field design strategy (elective nodal irradiation [ENI] versus involved-field [IF] TRT [IF-TRT]) and TRT dose (60 Gy versus ≥60 Gy). The primary end point of this analysis was the occurrence of AEs. ORs for AEs were calculated with univariable and multivariable logistic models. Results: TRT doses ranged from 60 to 74 Gy. ENI was not associated with more grade 3 or higher AEs than IF-TRT was (multivariable OR = 0.77, 95% confidence interval [CI]: 0.543–1.102, p = 0.1545). Doses higher than 60 Gy (high-dose TRT) were associated with significantly more grade 3 or higher AEs (multivariable OR = 1.82, 95% CI: 1.501–2.203, p < 0.0001). In contrast, ENI was associated with significantly more grade 4 or higher AEs (multivariable OR = 1.33, 95% CI: 1.035–1.709, p = 0.0258). Doses higher than 60 Gy were also associated with more grade 4 or higher AEs (multivariate OR = 1.42, 95% CI: 1.191–1.700, p = 0.0001). Grade 5 AEs plus treatment-related deaths were more frequent with higher-dose TRT (p = 0.0012) but not ENI (p = 0.099). Conclusions: For patients with LA-NSCLC treated with concurrent CRT, IF-TRT was not associated with the overall risk of grade 3 or higher AEs but was associated with significantly fewer grade 4 or higher AEs than ENI TRT. This is likely the result of irradiation of a lesser amount of adjacent critical normal tissue. Higher TRT doses were associated significantly with grade 3 or higher and grade 4 or higher AEs. On the basis of these findings and our prior report on survival, CRT using IF-TRT and 60 Gy (conventionally fractionated) were associated with more favorable patient survival and less toxicity than was the use of ENI or higher radiotherapy doses. | - |
dc.language | eng | - |
dc.publisher | Elsevier Inc. The Journal's web site is located at http://www.jto.org | - |
dc.relation.ispartof | Journal of Thoracic Oncology | - |
dc.subject | Non-small cell lung cancer | - |
dc.subject | Combined modality therapy | - |
dc.subject | Toxicity | - |
dc.subject | Adverse events | - |
dc.subject | Doses | - |
dc.title | Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non–Small Cell Lung Cancer | - |
dc.type | Article | - |
dc.identifier.email | Pang, HH: herbpang@hku.hk | - |
dc.identifier.authority | Pang, HH=rp01857 | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1016/j.jtho.2018.09.021 | - |
dc.identifier.pmid | 30292852 | - |
dc.identifier.pmcid | PMC6348032 | - |
dc.identifier.scopus | eid_2-s2.0-85056510211 | - |
dc.identifier.hkuros | 309583 | - |
dc.identifier.volume | 14 | - |
dc.identifier.issue | 2 | - |
dc.identifier.spage | 298 | - |
dc.identifier.epage | 303 | - |
dc.identifier.isi | WOS:000456410800028 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1556-0864 | - |